Xilio Therapeutics, Inc.
XLOHealthcare|Biotechnology|US
$8.62
+0.12 (+1.41%)
DCF Value
$329.92
Tangible Book / Share
$3.72
Cash / Share
$7.01
Financials
Financial Snapshot
Market Cap
$56.7M
Enterprise Value
-$73.0M
Revenue (TTM)
$64.1M
Net Income (TTM)
-$21.8M
Cash & Investments
$136.0M
Net Cash
$129.7M
Free Cash Flow (TTM)
-$61.3M
Operating CF (TTM)
-$60.6M
Debt/Equity
0.09
Cash Runway & Burn Rate
Cash on Hand
$136.0M
Quarterly Burn
$15.1M
Monthly Burn
$5.0M
Est. Runway
~9.0 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $48.8M | $19.2M | $198.1M | $120.4M | $44.7M | $55.3M | $137.5M | $136.0M | |
| Operating Cash Flow | -$17.8M | -$36.1M | -$80.8M | -$75.7M | -$68.6M | -$18.4M | -$5.0M | -$60.6M | |
| Free Cash Flow | -$18.6M | -$38.3M | -$81.9M | -$77.6M | -$69.1M | -$18.4M | -$5.5M | -$61.3M | |
| Capital Expenditure | -$715.0K | -$2.2M | -$1.1M | -$1.9M | -$486.0K | -$36.0K | -$518.0K | -$670.0K | |
| Financing Cash Flow | $60.0M | $10.0M | $260.7M | -$69.0K | -$6.5M | $29.2M | $87.8M | $75.8M |
R&D Spending
R&D (TTM)
$66.8M
R&D Intensity
104.3%
R&D Growth vs Prior
+19.3%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.3M | $43.8M | $64.1M | |
| R&D Expense | $14.3M | $43.9M | $51.2M | $59.2M | $52.1M | $41.2M | $56.0M | $66.8M | |
| R&D % of Revenue | — | — | — | — | — | 649.6% | 128.0% | 104.3% | |
| SG&A | $4.5M | $9.6M | $22.4M | $29.9M | $27.0M | $24.8M | $29.7M | $28.3M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.3M | $43.8M | $64.1M | |
| Cost of Revenue | $240.0K | $1.1M | $1.5M | $0.00 | $0.00 | $0.00 | $1.5M | $344.0K | |
| Gross Profit | -$240.0K | -$1.1M | -$1.5M | $0.00 | $0.00 | $6.3M | $42.2M | $63.7M | |
| R&D | $14.3M | $43.9M | $51.2M | $59.2M | $52.1M | $41.2M | $56.0M | $66.8M | |
| SG&A | $4.5M | $9.6M | $22.4M | $29.9M | $27.0M | $24.8M | $29.7M | $28.3M | |
| Operating Income | -$19.0M | -$54.6M | -$75.0M | -$89.1M | -$79.1M | -$60.6M | -$42.0M | -$31.4M | |
| Interest Expense | $0.00 | $600.0K | $600.0K | $0.00 | $0.00 | $100.0K | $0.00 | $0.00 | |
| Pretax Income | -$17.3M | -$55.2M | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M | -$21.8M | |
| Net Income | -$17.3M | -$55.2M | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M | -$21.8M | |
| EPS (Diluted) | -592.06 | -1475.88 | -189.28 | -45.08 | -38.92 | -15.26 | -4.19 | -1.64 | |
| EBITDA | -$17.1M | -$53.6M | -$73.7M | -$86.4M | -$74.5M | -$58.0M | -$33.5M | -$20.5M | |
| Shares Out. (M) | 0.03 | 0.04 | 0.40 | 1.96 | 1.96 | 3.82 | 8.36 | 19.40 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.8M | $19.2M | $198.1M | $120.4M | $44.7M | $55.3M | $137.5M | $136.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $51.1M | $20.6M | $202.5M | $124.5M | $48.1M | $60.2M | $145.0M | $145.5M | |
| Total Assets | $62.7M | $36.3M | $221.6M | $139.2M | $60.9M | $71.1M | $154.7M | $154.3M | |
| Total Current Liabilities | $5.2M | $22.2M | $12.8M | $21.1M | $16.0M | $27.3M | $56.3M | $34.2M | |
| Long-Term Debt | $9.6M | $7.8M | $9.6M | $3.2M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $24.2M | $41.6M | $36.2M | $33.5M | $24.1M | $53.5M | $119.4M | $82.0M | |
| Stockholders' Equity | $38.5M | -$5.3M | $185.4M | $105.6M | $36.8M | $17.6M | $35.3M | $72.3M | |
| Retained Earnings | -$29.9M | -$85.1M | -$160.9M | -$249.1M | -$325.5M | -$383.8M | -$418.8M | -$434.7M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$17.8M | -$36.1M | -$80.8M | -$75.7M | -$68.6M | -$18.4M | -$5.0M | -$60.6M | |
| Capital Expenditure | -$715.0K | -$2.2M | -$1.1M | -$1.9M | -$486.0K | -$36.0K | -$518.0K | -$670.0K | |
| Free Cash Flow | -$18.6M | -$38.3M | -$81.9M | -$77.6M | -$69.1M | -$18.4M | -$5.5M | -$61.3M | |
| Investing Cash Flow | -$715.0K | -$2.2M | -$1.1M | -$1.9M | -$486.0K | -$36.0K | -$518.0K | -$670.0K | |
| Financing Cash Flow | $60.0M | $10.0M | $260.7M | -$69.0K | -$6.5M | $29.2M | $87.8M | $75.8M | |
| Issuance of Stock | $0.00 | $0.00 | $116.4M | $16.0K | $202.0K | $6.8M | $87.8M | $77.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $10.0M | -$99.0K | -$110.0K | -$85.0K | -$6.8M | -$3.4M | $0.00 | $0.00 | |
| Stock Based Comp. | $112.0K | $1.3M | $5.0M | $8.4M | $7.4M | $6.4M | $6.9M | $7.9M | |
| Net Change in Cash | $41.5M | -$28.3M | $178.8M | -$77.7M | -$75.7M | $10.8M | $82.3M | $14.5M |
Dilution Tracker
Shares outstanding grew 22242.7% over 5 years — significant dilution
Shares Outstanding
7M
5-Year Share Growth
+22242.7%
Stock Issuance (TTM)
$77.3M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.03 | 0.04 | 0.40 | 1.96 | 1.96 | 3.82 | 8.36 | 19.40 | |
| Change vs Prior % | — | 28.0% | 970.4% | 388.7% | 0.4% | 94.6% | 118.7% | 132.1% | |
| Stock Issuance | $0.00 | $0.00 | $116.4M | $16.0K | $202.0K | $6.8M | $87.8M | $77.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $112.0K | $1.3M | $5.0M | $8.4M | $7.4M | $6.4M | $6.9M | $7.9M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | 100.0% | 96.5% | 99.5% | |
| Operating Margin % | — | — | — | — | — | -954.9% | -95.9% | -48.9% | |
| Net Margin % | — | — | — | — | — | -918.0% | -80.1% | -34.1% | |
| EBITDA Margin % | — | — | — | — | — | -914.3% | -76.5% | -32.0% | |
| FCF Margin % | — | — | — | — | — | -290.3% | -12.6% | -95.6% | |
| ROE % | -45.0% | 1044.8% | -40.9% | -83.5% | -207.5% | -331.0% | -99.3% | -50.8% | |
| ROA % | -27.6% | -152.0% | -34.2% | -63.4% | -125.4% | -81.9% | -22.6% | -14.2% | |
| ROIC % | -33.1% | -318.3% | -35.8% | -71.0% | -160.4% | -134.6% | -42.1% | -25.8% | |
| R&D / Revenue % | — | — | — | — | — | 649.6% | 128.0% | 104.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 589.9% | |
| Gross Profit | 0.0% | -343.8% | -40.8% | 100.0% | 0.0% | 0.0% | 565.6% | |
| Operating Income | 0.0% | -186.8% | -37.5% | -18.8% | 11.2% | 23.4% | 30.7% | |
| Net Income | 0.0% | -219.0% | -37.3% | -16.4% | 13.4% | 23.8% | 39.8% | |
| EPS (Diluted) | 0.0% | -149.3% | 87.2% | 76.2% | 13.7% | 60.8% | 72.5% | |
| Operating Cash Flow | 0.0% | -102.3% | -123.7% | 6.2% | 9.4% | 73.2% | 72.8% | |
| Free Cash Flow | 0.0% | -106.3% | -113.8% | 5.2% | 10.9% | 73.4% | 70.1% | |
| R&D Expense | 0.0% | 208.0% | 16.6% | 15.7% | -11.9% | -21.0% | 36.0% | |
| SG&A Expense | 0.0% | 111.6% | 133.2% | 34.0% | -9.9% | -8.2% | 19.9% | |
| Total Assets | 0.0% | -42.1% | 510.2% | -37.2% | -56.2% | 16.7% | 117.6% | |
| Book Value / Share | 0.0% | -110.7% | 427.8% | -88.3% | -65.3% | -75.4% | -8.4% | |
| Debt | 0.0% | 17.5% | -5.3% | -3.8% | -37.3% | -34.9% | -14.6% | |
| Diluted Shares | 0.0% | 28.0% | 970.4% | 388.7% | 0.4% | 94.6% | 118.7% |
Valuation
P/E (TTM)At Loss
P/S0.88
P/B2.31
10Y Low / Med / High0.17 / 0.70 / 2.90
EV/EBITDA3.56
10Y Low / Med / High0.23 / 1.19 / 1.66
EV/Revenue-1.14
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$329.92
Tangible Book / Share
$3.72
Net Current Assets / Share
$9.65
Graham Net-Net
$3.02
Cash / Share
$7.01
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.38 | -0.15 | -1.18 | -0.84 | -0.20 | -0.88 | -2.14 | -5.79 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.05 | 1.71 | 0.88 | |
| P/B Ratio | 0.17 | -1.59 | 0.48 | 0.70 | 0.41 | 2.90 | 2.12 | 2.31 | |
| EV/EBITDA | 1.39 | -0.21 | 1.19 | 0.31 | 0.23 | -0.07 | 1.66 | 3.56 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.62 | -1.27 | -1.14 |
Analyst Estimates & Quality
Altman Z-Score
-2.72
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $40.3M | $49.5M | $7.2M |
| Net Income | -$24.1M | -$16.6M | -$25.1M |
| EPS | $-2.88 | $-1.98 | $-3.00 |
| # Analysts (EPS) | 1 | 1 | 2 |